title: Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.
abstract: OBJECTIVE
  Tβ4 is an integral factor in repair of myocardium in animal models. To investigate whether Tβ4 is important in human cardiac disease and has a role in mediating the beneficial cardiac effects of bone-marrow-derived stem cell (BMSC) therapy, we measured serial plasma Tβ4 levels in patients enrolled on the REGENERATE-IHD cell therapy trial.
  
  
  METHODS
  Plasma Tβ4 concentrations were measured in 13 patients who received BMSCs and 14 controls.
  
  
  RESULTS
  There was a significant increase in plasma Tβ4 in the BMSC group 24 h after intracardiac injection. Increases in Tβ4 levels were associated with improvement in New York Heart Association symptom class.
  
  
  CONCLUSIONS
  This exploratory study highlights the need for further study of Tβ4 in human cardiovascular disease.
authors.affiliation: 1Department of Cardiology, London Chest Hospital, Barts Health Trust, London, E2 9JX, UK.
authors.forename: Fizzah A
authors.initials: FA
authors.lastname: Choudry
authors.affiliation: 1Department of Cardiology, London Chest Hospital, Barts Health Trust, London, E2 9JX, UK.
authors.forename: Chia
authors.initials: C
authors.lastname: Yeo
authors.affiliation: 1Department of Cardiology, London Chest Hospital, Barts Health Trust, London, E2 9JX, UK.
authors.forename: Abdul
authors.initials: A
authors.lastname: Mozid
authors.affiliation: 2British Heart Foundation Laboratories, Department of Medicine, University College London, London, WC1E 6JJ, UK.
authors.forename: John F
authors.initials: JF
authors.lastname: Martin
authors.affiliation: 1Department of Cardiology, London Chest Hospital, Barts Health Trust, London, E2 9JX, UK.|3Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
authors.forename: Anthony
authors.initials: A
authors.lastname: Mathur
mesh_terms: D000368:Aged; D001854:Bone Marrow Cells / Q000166:cytology; D002452:Cell Count; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D009206:Myocardium / Q000473:pathology*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D033581:Stem Cell Transplantation; D013947:Thymosin / Q000097:blood*; D016896:Treatment Outcome; D000099201:Thymosin beta(4)
chemical_list: D020097:Natriuretic Peptide, Brain; D010446:Peptide Fragments; D013947:Thymosin; D000099201:Thymosin beta(4); C109794:pro-brain natriuretic peptide (1-76)
keywords: ischemic heart failure; stem cell therapy; thymosin β4